Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories.

Precision oncology holds great potential to improve patient therapies and outcomes. Tumor sequencing is rapidly moving into clinical care as our understanding of the cancer genome and the availability of targeted therapies increase. Analysis of the cancer genome is most informative when paired with germline genomic DNA to delineate inherited and somatic variants. Although tumor-only analysis remains the most common methodology for numerous reasons, it holds the potential to identify clinically significant germline variants. Here, we provide anticipatory guidance and points to consider for laboratories and clinicians regarding the potential for germline findings in tumor sequencing.

[1]  Shashikant Kulkarni,et al.  Good laboratory practice for clinical next-generation sequencing informatics pipelines , 2015, Nature Biotechnology.

[2]  Theresa Zhang,et al.  Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation. , 2015 .

[3]  Donavan T. Cheng,et al.  Tumor relevant germline findings in targeted tumor sequencing using matched normal DNA of 1,570 unselected cases. , 2015 .

[4]  G. Mills,et al.  Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. , 2015 .

[5]  Sarah Watson,et al.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer , 2015, Nature Reviews Clinical Oncology.

[6]  O. Olopade,et al.  Tumor genome analysis includes germline genome: Are we ready for surprises? , 2014, International journal of cancer.

[7]  M. Robson,et al.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. , 2010, Journal of Clinical Oncology.

[8]  Paolo Rocco,et al.  Good laboratory practice for clinical next-generation sequencing informatics pipelines , 2015 .

[9]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[10]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[11]  James X. Sun,et al.  Abstract 1893: A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer specimens without a matched normal control , 2014 .

[12]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[13]  Y. Bombard,et al.  Revealing the incidentalome when targeting the tumor genome. , 2013, JAMA.

[14]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[15]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Ian Tomlinson,et al.  Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers , 2013, The Journal of pathology.

[17]  E. V. Van Allen,et al.  Clinical analysis and interpretation of cancer genome data. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[19]  Shashikant Kulkarni,et al.  Assuring the quality of next-generation sequencing in clinical laboratory practice , 2012, Nature Biotechnology.

[20]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[21]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[22]  David T. W. Jones,et al.  Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.

[23]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[24]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[25]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Holly Neibergs,et al.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 , 2004 .

[27]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.